[HT-10-4] Investigation and Drug Development of ALS using iPSCs technology and Clinical Trial
A recent advance in understanding the pathogenesis of various motor neuron diseases has lead to groundbreaking therapies for motor neuron diseases, including spinobulbar muscular atrophy and spinal muscular atrophy. In ALS, the antisense oligonucleotide therapy and high thruput drug screening using iPS attract huge attention as a promising therapy. This symposium is focussing on therapeutic advances based on the recent innovative translational researches.
Employment:
2017~: Dean, Keio University Graduate School of Medicine.
2015~2017: Dean, Keio University School of Medicine.
2017~: Visiting Professor, Peking University
2009~: Visiting Professor, University of New South Wales
2008~: Honorary Professor, the Queenland Brain Institute
2007~ 2015: Dean, Keio University Graduate School of Medicine.
2001~: Professor, Dept of Physiology, Keio University School of Medicine.
1997-2001: Professor, Dept of Neuroscience, Osaka University Graduate School of Medicine
1994-1997: Professor, Dept of Molecular Neurobiology, University of Tsukuba.
1992-1994: Instructor, Dept of Molecular Neurobiology, Institute of Medical Science, University of Tokyo.
1989-1993: Postdoctoral Research Fellow, Dept of Biological Chemistry, The Johns Hopkins University School of Medicine.
1985-1989: Instructor, Institute for Protein Research, Osaka University.
1983-1985: Instructor, Deptof Physiology, Keio University School of Medicine.
Abstract password authentication.
Password is written on a pocket program and name badge.